Showing 2401-2410 of 5623 results for "".
- Tarsus Pharmaceuticals Presents Data from Two Studies on the Prevalence and Impact of Demodex Blepharitishttps://modernod.com/news/tarsus-pharmaceuticals-presents-data-from-two-studies-on-the-prevalence-and-impact-of-demodex-blepharitis/2480402/Tarsus Pharmaceuticals presented data today from two pioneering studies on the prevalence and impact of Demodex blepharitis at the American Academy of Optometry (AAOpt) 2021 Annual Meeting in Boston. The Titan real-world prevalence study data revealed that Demodex blepharitis accounts for ov
- Visus Therapeutics Appoints David Guyer, MD, as Chairman of the Board, and Names Ted Danse as Head of Business Developmenthttps://modernod.com/news/visus-therapeutics-appoints-david-guyer-md-as-chairman-of-the-board-and-names-ted-danse-as-head-of-business-development/2480395/Visus Therapeutics announced the appointment of ophthalmology and industry expert David Guyer, MD, as the chairman of the Board after serving as an advisor since the company’s inception, and life sciences veteran Ted Danse as the head of business development. “I&rs
- IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injuryhttps://modernod.com/news/iacta-pharmaceuticals-receives-us-department-of-defense-funding-of-1-million-to-conduct-preclinical-studies-of-ic-800-to-treat-pain-relief-for-eye-injury/2480382/IACTA Pharmaceuticals announced that the U.S. Army Medical Research Acquisition Activity (USAMRAA), a division of the Department of Defense, has granted a $1 million award to the company to fund preclinical studies of IC 800, a novel therapy for the topical treatment of ocular pain utilizing
- Tilak Healthcare Raises €7m to Deploy Its Remote Vision Monitoring Platformhttps://modernod.com/news/tilak-healthcare-raises-eur7m-to-deploy-its-remote-vision-monitoring-platform/2480381/Tilak Healthcare, a developer of mobile games with medical modules to monitor patients with chronic ophthalmological conditions, has announced a €7 million fundraising round managed by Elaia, with the participation of Swen Capital Partners, Matmut Innovation, and co-founder
- Collaboration Agreement Aims to Develop Orally Administered Treatment for Diabetic Macular Edema and Wet AMDhttps://modernod.com/news/collaboration-agreement-aims-to-develop-orally-administered-treatment-for-diabetic-macular-edema-and-wet-amd/2480380/Korea-based biopharmaceutical company Curacle announced that it has entered into an exclusive license and collaboration agreement with Théa Open Innovation (TOI) for the development and commercialization of Curacle's CU06-RE, which is being examined as an orall
- Eyenovia Announces Reclassification of MydCombi as Drug-Device Combination Product by FDAhttps://modernod.com/news/eyenovia-announces-reclassification-of-mydcombi-as-drug-device-combination-product-by-fda/2480375/In a Complete Response Letter (CRL) from the FDA, Eyenovia announced that MydCombi, the company’s proprietary, first-in-class combination microdose formulation of tropicamide and phenylephrine for in-office pupil dilation, has been reclassified as a drug-device com
- FDA Approves Genentech’s Port Delivery System, Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet AMDhttps://modernod.com/news/fda-approves-genentechs-port-delivery-system-susvimo-a-first-of-its-kind-therapeutic-approach-for-wet-amd/2480373/Genentech announced that the FDA has approved Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use via ocular implant for the treatment of people with wet age-related macular degeneration (AMD) who have previously responded to at least two anti-vascular endothelial growth fact
- Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of Iluvien to Significantly Reduce Treatment Burden in Patients with DMEhttps://modernod.com/news/recent-24-month-real-world-paladin-data-demonstrate-the-ability-of-iluvien-to-significantly-reduce-treatment-burden-in-patients-with-dme/2480348/Alimera Sciences announced a data presentation at the American Society of Retina Specialists (ASRS) demonstrating significant reductions in treatment burden in patients receiving Iluvien for diabetic macular edema (DME). The real-world data from the phase 4 PALADIN study
- Ocular Therapeutix Gains New Indication for Dextenza to Include Treatment of Ocular Itching Associated with Allergic Conjunctivitishttps://modernod.com/news/ocular-therapeutix-nabs-new-indication-for-dextenza-to-include-treatment-of-ocular-itching-associated-with-allergic-conjunctivitis/2480340/Ocular Therapeutix announced the FDA has approved its supplemental new drug application (sNDA) to broaden the Dextenza label to add an additional indication for the treatment of ocular itching associated with allergic conjunctivitis. With the approval, Dextenza is the first, FDA-approve
- Apellis Announces Detailed Results from Phase 3 DERBY and OAKS Studieshttps://modernod.com/news/apellis-announces-detailed-results-from-phase-3-derby-and-oaks-studies-presented-at-retina-society-annual-meeting/2480313/Apellis Pharmaceuticals announced that detailed data from the phase 3 DERBY and OAKS studies were presented for the first time as part of two oral presentations at the Retina Society Annual Scientific Meeting in Chicago.The studies evaluated the efficacy and safety of pegcetacoplan, an investigat